Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber - Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber Stallergenes S.A.announces the highly positive results of a new study conducted in an Allergen Challenge...
Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber - Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber Stallergenes S.A.announces the highly positive results of a new study conducted in an Allergen Challenge...
Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber - Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber Stallergenes S.A.announces the highly positive results of a new study conducted in an Allergen Challenge...
Ed Blonz: Unproven cancer treatment preys on hope Q: The father of a close friend has bladder cancer, and he has been downing a daily dose of a product called Poly -MVA.There is concern in the family, and I told her I would check with my sources.
I have not found much on this.
High Levels of Cancer-Causing Chemicals Found in Donna Lake HIDALGO COUNTY - Federal officials warn everyone not to eat fish caught in Donna Lake or the irrigation canals, because they contain high levels of chemicals known to cause cancer.The government has yet to figure where the chemicals are...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Loss -(T-Net)--Nventa Biopharmaceuticals (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and corporate milestones.Recent product and...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig SAN DIEGO, Aug.12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig SAN DIEGO, Aug.12, 2008 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig - 07:45 EST SAN DIEGO, Aug.12 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig SAN DIEGO, Aug.12 CA-Nventa-earnings SAN DIEGO, Aug.
12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig SAN DIEGO, Aug.12 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN - News) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig SAN DIEGO, Aug.12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments...
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial SAN DIEGO, August 12 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (News) (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial - Nventa Biopharmaceuticals Corporation announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate.HspE7 is a therapeutic treatment for patients...
Nventa reports positive results from Phase I cervical dysplasia trial Nventa Biopharmaceuticals has completed analysis of immunological data from all four cohorts of its Phase I clinical trial for HspE7, its lead product candidate for treatment of patients with cervical intraepithelial neoplasia or CIN, a...
Nventa reports positive results from Phase I cervical dysplasia trial The purpose of the Phase I trial was to determine the safety, tolerability and immunogenicity of HspE7 plus escalating doses of adjuvant (50, 500, 1,000 and 2,000mcg of Poly -ICLC).All dose regimens were found to be safe and well...
Nventa Wins European Patent Challenge Covering Lead Product Candidate HspE7 and Other HPV Therapeutics /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office (EPO) for the company's European Patent Number 1,002...
HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer! (Prudent Press Agency)---HAMPTON, Va.--HST Global, Inc., (OTCBB: HTSC) announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients.The highlight of the study is in stage IV breast...
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate...
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial -- Company Provides Update to Phase 2 Development Plan -- SAN DIEGO, July 28, 2008 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation today announced that it has completed analysis of immunological data from all four cohorts of...
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate.HspE7 is a therapeutic...
Nventa Wins European Patent Challenge Covering Lead Product Candidate HspE7 and Other HPV Therapeutics /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office (EPO) for the company's European Patent Number 1,002...
As Neros Moves to Change Pharma Industry (This Day/All Africa Global Media via COMTEX News Network) -- The company, Neros Pharmaceuticals, is not new to the drug sector in the country.After years of operations in the marketing of over 71 pharmaceutical brands in the country, the...
CORRECTING and REPLACING HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer! HST GLOBAL, INC.SETS NEW STANDARDS IN THE TREATMENT OF STAGE IV BREAST CANCER!
HST Global, Inc., (OTCBB: HSTC) announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients!
The...
CORRECTING and REPLACING HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer! Company Website: http://www.hstglobal.com HAMPTON, Va.-- (Business Wire) Reissuing release to correct ticker symbol for searching purposes.
The correctedrelease reads: HST GLOBAL, INC.
SETS NEW STANDARDS IN THE TREATMENT OF STAGE IV...
